OBJECTIVES: Evaluation of outcomes in the use of single-agent gemcitabine for the treatment of AIDS-associated Kaposi's sarcoma (KS) in a western Kenyan cancer treatment program. METHODS: Retrospective chart review of all patients with KS treated with single agent gemcitabine following failure of first-line Adriamycin, bleomycin, and vincristine (ABV). Baseline demographics were collected, and clinicians' assessments of response were utilized to fill out objective criteria for both response as well as symptom benefit assessment. RESULTS: Twenty-three patients with KS who had previously failed first-line therapy with ABV were evaluated. Following treatment, 22 of the 23 patients responded positively to treatment with stable disease or better. Of the 18 patients who had completed therapy, with a median follow-up of 5 months, 12 patients had no documented progression. CONCLUSIONS: Treatment options in the resource-constrained setting are limited, both by financial constraints as well as the need to avoid myelotoxicity, which is associated with high morbidity in this treatment setting. This work shows that gemcitabine has promising activity in KS, with both objective responses and clinical benefit observed in this care setting. Gemcitabine as a single agent merits further investigation for AIDS-associated KS. Copyright 2010 S. Karger AG, Basel.
OBJECTIVES: Evaluation of outcomes in the use of single-agent gemcitabine for the treatment of AIDS-associated Kaposi's sarcoma (KS) in a western Kenyan cancer treatment program. METHODS: Retrospective chart review of all patients with KS treated with single agent gemcitabine following failure of first-line Adriamycin, bleomycin, and vincristine (ABV). Baseline demographics were collected, and clinicians' assessments of response were utilized to fill out objective criteria for both response as well as symptom benefit assessment. RESULTS: Twenty-three patients with KS who had previously failed first-line therapy with ABV were evaluated. Following treatment, 22 of the 23 patients responded positively to treatment with stable disease or better. Of the 18 patients who had completed therapy, with a median follow-up of 5 months, 12 patients had no documented progression. CONCLUSIONS: Treatment options in the resource-constrained setting are limited, both by financial constraints as well as the need to avoid myelotoxicity, which is associated with high morbidity in this treatment setting. This work shows that gemcitabine has promising activity in KS, with both objective responses and clinical benefit observed in this care setting. Gemcitabine as a single agent merits further investigation for AIDS-associated KS. Copyright 2010 S. Karger AG, Basel.
Authors: Susan E Krown; Carlee B Moser; Patrick MacPhail; Roy M Matining; Catherine Godfrey; Stephanie R Caruso; Mina C Hosseinipour; Wadzanai Samaneka; Mulinda Nyirenda; Naftali W Busakhala; Fred M Okuku; Josphat Kosgei; Brenda Hoagland; Noluthando Mwelase; Vincent O Oliver; Henriette Burger; Rosie Mngqibisa; Mostafa Nokta; Thomas B Campbell; Margaret Z Borok Journal: Lancet Date: 2020-03-05 Impact factor: 79.321
Authors: Michael E Herce; Noel Kalanga; Emily B Wroe; James W Keck; Felix Chingoli; Listern Tengatenga; Satish Gopal; Atupere Phiri; Bright Mailosi; Junior Bazile; Jason A Beste; Shekinah N Elmore; Jonathan T Crocker; Jonas Rigodon Journal: J Int AIDS Soc Date: 2015-05-29 Impact factor: 5.396
Authors: Naftali Busakhala; Gabriel Kigen; Paul Waako; R Matthew Strother; Fredrick Chite; Patrick Loehrer Journal: Infect Agent Cancer Date: 2019-09-10 Impact factor: 2.965
Authors: Naftali W Busakhala; Paul J Waako; Matthew Robert Strother; Alfred Kipyegon Keter; Gabriel Kimutai Kigen; Fredrick Chite Asirwa; Patrick J Loehrer Journal: J Glob Oncol Date: 2018-09